Cue Biopharma, Inc. (CUE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on April 22, 2026. The filing addresses a material modification to the rights of security holders and amendments to the Company's Articles of Incorporation. The primary event is the implementation of a reverse stock split to maintain compliance with Nasdaq Capital Market listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, the "Cautionary Note Regarding Forward Looking Statements" explicitly references the Company's "limited cash and a history of losses" and its current "going concern" determination, indicating insufficient capital to continue operations beyond the next twelve months without additional financing.
Material Changes
- Reverse Stock Split: A 1-for-30 reverse stock split of issued and outstanding common stock was effected as of 5:00 p.m. Eastern Time on April 23, 2026.
- Share Reclassification: Every thirty shares of Common Stock were automatically reclassified into one share. No fractional shares were issued; cash payments were made in lieu of fractional shares.
- Adjustments to Derivatives: Outstanding stock options and warrants were adjusted to proportionately reduce the number of shares issuable and increase the exercise price.
- Equity Plans: The total number of shares available for future grants under equity incentive plans was proportionately decreased.
- Trading Details: Common Stock began trading on a post-split basis on April 24, 2026, under the symbol "CUE" with a new CUSIP number (22978P205).
Outlook, Risks, and Management Commentary
Management states the reverse split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The filing highlights significant risks, including:
- Going Concern: The Company faces a determination that it does not have sufficient capital to continue operations beyond the next twelve months.
- Financing Needs: There is a risk regarding the ability to obtain adequate financing to fund future business operations.
- Operational Risks: Risks include limited operating history, reliance on collaborators (specifically ImmunoScape), and potential setbacks in research and development or clinical trials.
Investor Verification Checklist
- Verify the post-split share count and the new CUSIP number (22978P205) in brokerage accounts.
- Confirm the adjusted exercise prices and share counts for any held stock options or warrants.
- Review the Company's most recent Form 10-K and 10-Q for details on the "going concern" warning and current cash runway.
- Monitor upcoming filings for updates on the Company's ability to secure additional financing to sustain operations.
- Check the status of the collaboration with ImmunoScape as a key operational dependency.